Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cough medicine
Biotech
Seyltx gains option to boost cough pipeline with 8 NeurOp drugs
Cough-focused biotech Seyltx has secured the option to license a portfolio of eight GluN2B antagonists from NeurOp.
James Waldron
Jun 5, 2025 10:40am
Roche culls cough candidate, pivots KRAS program in Q3 update
Oct 23, 2024 6:35am
After $2B acquisition, GSK sends some Bellus workers packing
Mar 22, 2024 11:08am
GSK tips 12 blockbuster launches to soften HIV patent loss
Jan 31, 2024 7:45am
Merck’s cough drug gefapixant rejected by FDA for second time
Dec 21, 2023 5:38am
After Merck's cough drama, GSK knew what to do with Bellus asset
Nov 30, 2023 8:00am
